{
    "clinical_study": {
        "@rank": "75467", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin type A (Botulax\u00ae)", 
                "arm_group_type": "Experimental", 
                "description": "Botulinum toxin type A (Botulax\u00ae)"
            }, 
            {
                "arm_group_label": "Botulinum toxin type A(Botox\u00ae)", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum toxin type A(Botox\u00ae)"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the safety and efficacy of Botulax Inj.\u00ae(Botulinum toxin type A, Hugel, South\n      Korea) with Botox Inj.\u00ae (Botulinum toxin type A, Allergan, USA) in the treatment of cerebral\n      palsy in children."
        }, 
        "brief_title": "Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of \"Botulax\u00ae\" in Children With Cerebral Palsy", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Other Infantile Cerebral Palsy", 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Palsy", 
                "Paralysis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Children patients ages from 2years old to 10years old.\n\n          2. Patients who diagnosed with cerebral palsy.\n\n          3. Patients who diagnosed as Gross Motor Function Classification System level I, II, or\n             III\n\n          4. Patients who diagnosed as dynamic equinus foot deformity\n\n          5. Patients who agree with participation and signed to written agreement by substitute.\n             (Get a signature from children patients if possible)deformity and I, II or III level\n             of Gross Motor Function Classification System\n\n        Exclusion Criteria:\n\n          1. Patients who had previous injection of other botulinum toxin products in 3 months\n\n          2. Patients with hypersensitivity history to botulinum toxin products previously\n\n          3. Patients with neuromuscular junction disorder (myasthenia gravis, Lambert- Eaton\n             syndrome, or amyotrophic lateral sclerosis, etc.)\n\n          4. Those who have severe cardiovascular, kidney, liver, or respiratory diseases\n\n          5. Those who are taking anticoagulant drugs or have bleeding disorder.\n\n          6. Pratients with treatment of following drugs: Anticonvulsants, tranquilizers,\n             narcotics, aminoglycoside antibiotics, muscle relaxtants like baclofen, blockers of\n             parasympathetic nervous system, and levodopa.\n\n          7. Patients who had history of surgery, plan to have surgery on legs, foot, or ankle.\n\n          8. Patients who have evidence of fixed contractures regarding to Investigator\n\n          9. Patients who have difference between two legs over 5cm\n\n         10. Patients with severe athetoid movement\n\n         11. Patients who had other treatments related to dynamic equinus foot deformity, such as\n             alcohol injection or muscle relaxants\n\n         12. Those who were not enrolled in other studies within 30 days, or were not paseed over\n             5 times of half life for clinical trial drugs.\n\n         13. Patients who have possibility to take prevented drugs\n\n         14. Subjects who are not eligible for this study based on investigator's judgement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "10 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787344", 
            "org_study_id": "HG-11-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Botulinum toxin type A(Botox\u00ae)", 
                "description": "Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units", 
                "intervention_name": "Botulinum Toxin Type A(Botox\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Botulinum toxin type A (Botulax\u00ae)", 
                "description": "Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight idose n patients with diplegia, Maximum dosage 200units", 
                "intervention_name": "Botulinum toxin type A(Botulax\u00ae)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Bo-Young Hong", 
                    "phone": "031-249-7650"
                }, 
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Kyunggi"
                    }, 
                    "name": "St. Vincent's hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hyun-Jung Jang", 
                    "phone": "055-290-5565"
                }, 
                "facility": {
                    "address": {
                        "city": "Changwon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung medical center - Changwon"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "So-Young Lee", 
                    "phone": "053-250-7264"
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Keimyung University Dongsan Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sang-Ji Lee", 
                    "phone": "042-220-9264"
                }, 
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Catholic university of Korea, Daejeon St. Mary's hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ju-Hyun Park", 
                    "phone": "02-2258-6280"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "The Catholic University of Korea, Seoul St. Mary's hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jeong-yi Kwon", 
                    "phone": "02-3410-1030"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung medical center - Seoul"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of \"Botulax\u00ae\" Versus \"Botox\u00ae\" in Children With Cerebral Palsy.", 
        "overall_official": {
            "affiliation": "Samsung Medical Center -Seoul", 
            "last_name": "Jeong-yi Kwon, M.D., Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of patients with an improvement more than two grade in Physician's Rating Scale score.", 
            "safety_issue": "No", 
            "time_frame": "at 12 weeks post-injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787344"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of patients with an improvement more than two grade in Physician's Rating Scale score, comparing to baseline.", 
                "safety_issue": "No", 
                "time_frame": "at 6 and 24weeks post-injection"
            }, 
            {
                "measure": "Rate of change in Passive range of motion, compare to baseline.", 
                "safety_issue": "No", 
                "time_frame": "at 6, 12 and 24 weeks post-injection"
            }, 
            {
                "measure": "Rate of change in Gross Motor Function Measure 88, 66, compare to baseline.", 
                "safety_issue": "No", 
                "time_frame": "at 6, 12 and 24 weeks post-injection"
            }, 
            {
                "measure": "Rate of change in Modified Tardieu Scale(Ankle DF), compare to baseline.", 
                "safety_issue": "No", 
                "time_frame": "at 6, 12 and 24 weeks post-injection"
            }
        ], 
        "source": "Hugel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hugel", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}